Abstract | BACKGROUND:
Raltegravir has demonstrated potent and durable efficacy and a favorable safety profile in 3 phase III studies in treatment-naïve and treatment-experienced patients with HIV-1 infection. This manuscript provides a review of the raltegravir safety profile using data from these and other studies in the clinical development program. METHODS: RESULTS: CONCLUSIONS: Long-term data from the phase III clinical trials demonstrate that raltegravir was generally well-tolerated in both treatment-naïve and treatment-experienced patients with HIV infection.
|
Authors | Hedy Teppler, Deborah D Brown, Randi Y Leavitt, Peter Sklar, Hong Wan, Xia Xu, Fabio Lievano, Heidi P Lehman, T Christopher Mast, Bach-Yen T Nguyen |
Journal | Current HIV research
(Curr HIV Res)
Vol. 9
Issue 1
Pg. 40-53
(Jan 2011)
ISSN: 1873-4251 [Electronic] Netherlands |
PMID | 21198432
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-HIV Agents
- Pyrrolidinones
- Raltegravir Potassium
|
Topics |
- Adolescent
- Adult
- Aged
- Anti-HIV Agents
(administration & dosage, adverse effects)
- Clinical Trials, Phase III as Topic
- Female
- HIV Infections
(drug therapy)
- Humans
- Male
- Middle Aged
- Pyrrolidinones
(administration & dosage, adverse effects)
- Raltegravir Potassium
- Randomized Controlled Trials as Topic
- Young Adult
|